DMX-200 First 100 Patients Complete Phase 3 Trial Treatment

• First 100 patients complete 2-year double-blind treatment period
• 93% of patients elect to continue in Open Label Extension study
• Trial remains ongoing with patients continuing treatment

Dimerix Limited, a clinical-stage biopharmaceutical company, announced a significant milestone in its ACTION3 Phase 3 study of DMX-200 for focal segmental glomerulosclerosis (FSGS). The first 100 patients enrolled in the trial have successfully completed the full 2-year double-blind treatment period, marking an important clinical and operational achievement. Each patient completing the trial reduces the execution risk associated with long-duration trial retention and treatment adherence. Notably, 93% of these patients have elected to continue into the Open Label Extension (OLE) study, which provides access to DMX-200 treatment regardless of their initial assignment to placebo or DMX-200 during the trial. The OLE study will generate additional long-term safety and efficacy data, supporting future regulatory activities.